Clinical Scorecard: Patterns of Fragile X Syndrome Diagnosis in a Population-Based Cohort Across Multiple States
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Patterns of Fragile X Syndrome Diagnosis in a Population-Based Cohort Across Multiple States
Key Mechanisms
The study describes diagnosis patterns, not disease mechanisms. FXS is associated with FMR1; the study excluded premutation carriers identified by manual record review.
Target Population
Population described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
Among 7,381,668 patients, 231 had an FXS diagnosis recorded, compared with an estimated 839 expected cases.
The overall diagnosis rate was 27.5% (95% CI, 24.1%-31.2%).
Diagnosis rates were lower among Black patients than White patients: 17.9% versus 30.6% (P < .001).
Women had lower diagnosis rates than men overall and within each racial group.
The authors note limitations including reliance on diagnostic codes, data spanning more than five decades, and unknown actual FXS prevalence.
Guideline-Based Recommendations
Diagnosis
For study eligibility, the authors required at least two FXS encounters to improve diagnostic specificity and limit inclusion of rule-out testing.
The authors call for improved screening and diagnostic approaches, particularly for individuals without severe or classic phenotypes.
Management
The authors identify broader access to genetic testing and specialty care for underrepresented populations as a public health priority.
Monitoring & Follow-up
Risks
The article states that FXS is absent from routine newborn screening panels and that recommendations for genetic testing are frequently not fully implemented.
The authors note that milder or more variable phenotypes in women may limit clinical recognition.
The authors note that diagnosis rates may be affected by changes over time in clinician knowledge, genetic testing, and clinical practice, reliance on diagnostic codes, and uncertainty about actual FXS prevalence.
Patient & Prescribing Data
The cohort included 7,381,668 patients recorded as Black or African American (1,774,770) or White (5,606,898); the study did not evaluate prescribing.
No treatment or prescribing outcomes were assessed. The article discusses access to genetic testing and specialty care.
Clinical Best Practices
The study reported lower diagnosis rates among women than men and among Black patients than White patients; it does not establish individual diagnostic criteria.
Interpret reported diagnosis rates in light of reliance on coded diagnoses, data spanning more than five decades, and uncertainty about actual FXS prevalence.
The authors call for improved screening and diagnostic approaches and broader access to genetic testing and specialty care.
The report details a 13-year-old patient with newly diagnosed SLE who developed neuropsychiatric SLE (NP-SLE) – presenting with acute cerebellar dysfunction, impaired consciousness and nonconvulsive status epilepticus – despite initially atypical neuroimaging.
